Management Shake-Ups Consistent in RNAi, microRNA Markets Over Two Years
July 15, 2010
Management Shake-Ups Consistent in RNAi, microRNA Markets Over Two Years
Rosetta Genomics said that its chief commercialization officer would resign as the company settles into its latest change in corporate direction. But the company is not the only player in the RNAi/microRNA space to experience changes to its management lineup.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- As RNAi Rx Efforts Progress, Some Companies Look to Use Technologies in Other Areas
July 29, 2010 / Gene Silencing News - Snapshot: Partnership Goals, Track Records in the RNAi/miRNA Space
July 22, 2010 / Gene Silencing News - Despite Potential of RNAi, Companies in the Space Keep Pipelines Focused
March 11, 2010 / Gene Silencing News - Advances in microRNA Field Help Define 2009 While RNAi Advances Despite Setbacks
December 31, 2009 / Gene Silencing News - IP Update: Recent Patents, Patent Applications Awarded to CalTech, Alnylam, Silence, and More
January 24, 2013 / Gene Silencing News